OpenAI has made a significant investment in Merge Labs, a startup founded by CEO Sam Altman that focuses on advancing brain-computer interface (BCI) technology. Merge Labs aims to bridge biological and artificial intelligence to enhance human abilities, with OpenAI contributing the largest sum in Merge Labs’ $250 million seed round, valuing the company at $850 million.
Merge Labs envisions a future where interfacing with neurons at scale can restore lost abilities, support healthier brain states, deepen human connections, and expand creative capacities alongside advanced AI. The company plans to achieve these goals through noninvasive methods, using innovative technologies that connect with neurons utilizing molecules rather than electrodes, and transmit information using modalities like ultrasound.
Altman’s venture into BCIs through Merge Labs puts the company in direct competition with Elon Musk’s Neuralink, which also works on brain-computer interface technology but currently requires invasive surgery for implantation. While Neuralink focuses on medical applications, Merge Labs appears more interested in combining human biology with AI to unlock new capabilities.
OpenAI views BCIs as a crucial frontier that can revolutionize communication, learning, and interaction. The investment in Merge Labs signifies a growing interest in leveraging cutting-edge technology to enhance human potential and explore new ways of interfacing with AI.
Source: TechCrunch